<DOC>
	<DOC>NCT02808390</DOC>
	<brief_summary>This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 2 doses of GED-0507-34-Levo in subjects with active, mild-to-moderate UC.</brief_summary>
	<brief_title>Efficacy and Safety Study of GED-0507-34-Levo for Treatment of UC</brief_title>
	<detailed_description>This is a Phase 2, Proof of Concept, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 2 doses of GED-0507-34-Levo in subjects with active, mild-to-moderate Ulcerative Colitis. The study will consist of 3 phases: - Screening Phase - up to 4 weeks - Double-blind Placebo-controlled Phase - Weeks 0 to 8 - Follow-up Phase - Week 9</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Male or female aged 18 and over at the time of signing the informed consent. Diagnosis of UC with a duration of at least 3 months prior to the Screening Visit. MMS ≥ 4 to ≤ 8 (range: 0 9) prior to randomization in the study Subjects are required to have a colonoscopy if one has not been performed within 12 months prior to the Screening Visit. Subjects who have relapsed on maintenance therapy with doses of 5ASA &lt; 2.4 g/day Diagnosis of Crohn's disease, indeterminate colitis, ischemic colitis, microscopic colitis, radiation colitis, or diverticular diseaseassociated colitis. UC restricted to the distal 15 cm or less (eg, ulcerative proctitis). Subjects who have had surgery as a treatment for UC or who, in the opinion of the Investigator, are likely to require surgery for UC during the study. Clinical signs suggestive of fulminant colitis or toxic megacolon. Evidence of pathogenic enteric infection. History of colorectal cancer or colorectal dysplasia. Prior use of any TNF inhibitor (or any biologic agent). Prior use of mycophenolic acid, tacrolimus, sirolimus, cyclosporine, or thalidomide. Use of budesonideMMx within the last 8 weeks. Use of oral and/or IV corticosteroids within 2 weeks of the Screening Visit. Use of immunosuppressants (azathioprine [AZA], 6mercaptopurine [6MP] or methotrexate [MTX]) within 8 weeks of the Screening Visit.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>